Patents by Inventor Takafumi Motoki

Takafumi Motoki has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11479552
    Abstract: Provided are compounds represented by the following formulas (I), (II), (III) and (IV) having orexin type 2 receptor-activating activity, or their pharmaceutically acceptable salts.
    Type: Grant
    Filed: July 15, 2021
    Date of Patent: October 25, 2022
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Yu Yoshida, Yoichi Kita, Makoto Kotake, Keiichi Sorimachi, Toshiyuki Ohfusa, Takafumi Motoki, Taro Asaba
  • Publication number: 20220017517
    Abstract: Provided are compounds represented by the following formulas (I), (II), (III) and (IV) having orexin type 2 receptor-activating activity, or their pharmaceutically acceptable salts.
    Type: Application
    Filed: July 15, 2021
    Publication date: January 20, 2022
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Yu YOSHIDA, Yoichi KITA, Makoto KOTAKE, Keiichi SORIMACHI, Toshiyuki OHFUSA, Takafumi MOTOKI, Taro ASABA
  • Publication number: 20210255191
    Abstract: Disclosed is: a fluorescent dye comprising a compound, a tautomer of the compound, or a salt of the compound or the tautomer; a labeled composite substance comprising the fluorescent dye and a composite substance which are bonded to each other; a composition containing the fluorescent dye or the labeled composite substance; and a method for acquiring information about a substance of interest by a super-resolution microscopy.
    Type: Application
    Filed: February 1, 2021
    Publication date: August 19, 2021
    Applicants: Eisai R&D Management Co., Ltd., SYSMEX CORPORATION
    Inventors: Daiki HARA, Takafumi Motoki, Yuji Kazuta, Yoshihiko Norimine, Hiroyuki Amino, Masatoshi Suganuma, Shingo Fujiyama, Kazuto Yamashita, Masaya Okada, Yoichi Nishikawa, Shigeki Iwanaga
  • Patent number: 9458176
    Abstract: A compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof works as an mGluR2 antagonist, and is applicable as a therapeutic agent for neurological disorders related to glutamate dysfunction and diseases involving the mGluR2, such as Alzheimer's disease: wherein R is a hydrogen atom, a C1-6 alkyl group or the like, R1 is a C1-6 alkyl group, a C1-6 alkoxy group or the like, R2 is a halogen atom, a C1-6 alkyl group, a C1-6 alkoxy group or the like, R3 is a hydrogen atom, a C1-6 alkyl group or the like, and R4 is a C1-6 alkyl group or the like.
    Type: Grant
    Filed: February 26, 2014
    Date of Patent: October 4, 2016
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Mamoru Takaishi, Nobuhiro Sato, Tomoyuki Shibuguchi, Takafumi Motoki, Yoshinori Takahashi, Takeo Sasaki, Alan Braunton
  • Publication number: 20160052937
    Abstract: A compound represented by formula (I): wherein R is a methyl group or the like, R1 is a fluorine atom or the like, R2 is a hydrogen atom or a fluorine atom, R3 is a hydrogen atom, R4 is an ethyl group or the like, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: August 20, 2015
    Publication date: February 25, 2016
    Inventors: Mamoru Takaishi, Nobuhiro Sato, Takafumi Motoki, Tomoyuki Shibuguchi
  • Patent number: 8946211
    Abstract: A compound represented by the general formula: or a pharmaceutically acceptable salt thereof or a solvate thereof, wherein Ring A is a C6-14 aryl group or the like, L is —NReCO— or the like (wherein Re is a hydrogen atom or the like), Ring B is a C6-14 aryl group or the like, X is a C1-3 alkylene group or the like, Y is a single bond or the like, Z is a C1-3 alkylene group or the like, R1 and R2 are each independently a hydrogen atom or the like, and R3, R4, R5 and R6 are independently a hydrogen atom, a halogen atom or the like, has an A? production inhibitory effect or a BACE1 inhibitory effect and is useful as a prophylactic or therapeutic agent for a neurodegenerative disease caused by A? and typified by Alzheimer-type dementia.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: February 3, 2015
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Yuichi Suzuki, Takafumi Motoki, Toshihiko Kaneko, Mamoru Takaishi, Tasuku Ishida, Yoichi Kita, Kunitoshi Takeda, Noboru Yamamoto, Afzal Khan, Paschalis Dimopoulos
  • Patent number: 8946210
    Abstract: A compound represented by the general formula: or a pharmaceutically acceptable salt thereof or a solvate thereof, wherein Ring A is a C6-14 aryl group or the like, L is —NReCO— or the like (wherein Re is a hydrogen atom or the like), Ring B is a C6-14 aryl group or the like, X is a C1-3 alkylene group or the like, Y is a single bond or the like, Z is a C1-3 alkylene group or the like, R1 and R2 are each independently a hydrogen atom or the like, and R3, R4, R5 and R6 are independently a hydrogen atom, a halogen atom or the like, has an A? production inhibitory effect or a BACE1 inhibitory effect and is useful as a prophylactic or therapeutic agent for a neurodegenerative disease caused by A? and typified by Alzheimer-type dementia.
    Type: Grant
    Filed: December 21, 2011
    Date of Patent: February 3, 2015
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Yuichi Suzuki, Takafumi Motoki, Toshihiko Kaneko, Mamoru Takaishi, Tasuku Ishida, Yoichi Kita, Kunitoshi Takeda, Noboru Yamamoto, Afzal Khan, Paschalis Dimopoulos
  • Publication number: 20140243316
    Abstract: A compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof works as an mGluR2 antagonist, and is applicable as a therapeutic agent for neurological disorders related to glutamate dysfunction and diseases involving the mGluR2, such as Alzheimer's disease: wherein R is a hydrogen atom, a C1-6 alkyl group or the like, R1 is a C1-6 alkyl group, a C1-6 alkoxy group or the like, R2 is a halogen atom, a C1-6 alkyl group, a C1-6 alkoxy group or the like, R3 is a hydrogen atom, a C1-6 alkyl group or the like, and R4 is a C1-6 alkyl group or the like.
    Type: Application
    Filed: February 26, 2014
    Publication date: August 28, 2014
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Mamoru Takaishi, Nobuhiro Sato, Tomoyuki Shibuguchi, Takafumi Motoki, Yoshinori Takahashi, Takeo Sasaki, Alan Braunton
  • Patent number: 8501733
    Abstract: A compound represented by the general formula (I): or a pharmaceutically acceptable salt thereof, has an A? production inhibitory effect or a BACE1 inhibitory effect and is useful as a prophylactic or therapeutic agent for a neurodegenerative disease caused by A? and typified by Alzheimer-type dementia.
    Type: Grant
    Filed: July 24, 2009
    Date of Patent: August 6, 2013
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Takafumi Motoki, Toshihiko Kaneko, Noboru Yamamoto, Afzal Khan
  • Patent number: 8198269
    Abstract: A compound represented by the general formula: wherein Ring A is a C6-14 aryl group or the like, L is —NRLCO— or the like (wherein RL is a hydrogen atom or the like), Ring B is a C6-14 aryl group or the like, X is a C1-3 alkylene group or the like, Y is a C1-3 alkylene group or the like, Z is an oxygen atom or the like, R1 and R2 are each independently a hydrogen atom or the like, and R3, R4, R5 and R6 are independently a hydrogen atom, a halogen atom or the like, or a pharmaceutically acceptable salt thereof, or a solvate thereof, has an A? production inhibitory effect or a BACE1 inhibitory effect and is useful as a therapeutic agent for a neurodegenerative disease caused by A? and typified by Alzheimer-type dementia.
    Type: Grant
    Filed: September 28, 2009
    Date of Patent: June 12, 2012
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Takafumi Motoki, Kunitoshi Takeda, Yoichi Kita, Mamoru Takaishi, Yuichi Suzuki, Tasuku Ishida
  • Publication number: 20120094984
    Abstract: A compound represented by the general formula: or a pharmaceutically acceptable salt thereof or a solvate thereof, wherein Ring A is a C6-14 aryl group or the like, L is —NReCO— or the like (wherein Re is a hydrogen atom or the like), Ring B is a C6-14 aryl group or the like, X is a C1-3 alkylene group or the like, Y is a single bond or the like, Z is a C1-3 alkylene group or the like, R1 and R2 are each independently a hydrogen atom or the like, and R3, R4, R5 and R6 are independently a hydrogen atom, a halogen atom or the like, has an A? production inhibitory effect or a BACE1 inhibitory effect and is useful as a prophylactic or therapeutic agent for a neurodegenerative disease caused by A? and typified by Alzheimer-type dementia.
    Type: Application
    Filed: December 21, 2011
    Publication date: April 19, 2012
    Applicant: EISAI R&D MANAGEMENT CO., LTD.
    Inventors: Yuichi Suzuki, Takafumi Motoki, Toshihiko Kaneko, Mamoru Takaishi, Tasuku Ishida, Kunitoshi Takeda, Yoichi Kita, Noboru Yamamoto, Afzal Khan, Paschalis Dimopoulos
  • Patent number: 8158620
    Abstract: A compound represented by the general formula: or a pharmaceutically acceptable salt thereof or a solvate thereof, wherein Ring A is a C6-14 aryl group or the like, L is —NReCO— or the like (wherein Re is a hydrogen atom or the like), Ring B is a C6-14 aryl group or the like, X is a C1-3 alkylene group or the like, Y is a single bond or the like, Z is a C1-3 alkylene group or the like, R1 and R2 are each independently a hydrogen atom or the like, and R3, R4, R5 and R6 are independently a hydrogen atom, a halogen atom or the like, has an A? production inhibitory effect or a BACE1 inhibitory effect and is useful as a prophylactic or therapeutic agent for a neurodegenerative disease caused by A? and typified by Alzheimer-type dementia.
    Type: Grant
    Filed: January 16, 2009
    Date of Patent: April 17, 2012
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Yuichi Suzuki, Takafumi Motoki, Toshihiko Kaneko, Mamoru Takaishi, Tasuku Ishida, Kunitoshi Takeda, Yoichi Kita, Noboru Yamamoto, Afzal Khan, Paschalis Dimopoulos
  • Publication number: 20110207723
    Abstract: A compound represented by the general formula (I): a pharmaceutically acceptable salt thereof, or a solvate of the compound or salt has an A? production inhibitory activity or BACE 1 inhibitory activity, and is thus useful as an agent for treating neurodegenerative diseases caused by A? as typified by Alzheimer's disease. In the formula, ring A represents a C6-14 aryl group or the like; L represents —NR1CO— (wherein RL represents a hydrogen atom or the like) or the like; ring B represents a C6-14 aryl group or the like; X represents a C1-3 alkylene group or the like; Y represents a C1-3 alkylene group or the like; Z represents an oxygen atom or the like; R1 and R2 each independently represents a hydrogen atom or the like; and R3, R4, R5 and R6 each independently represents a hydrogen atom, a halogen atom or the like.
    Type: Application
    Filed: September 28, 2009
    Publication date: August 25, 2011
    Applicant: EISAI R&D MANAGEMENT CO., LTD.
    Inventors: Takafumi Motoki, Kunitoshi Takeda, Yoichi Kita, Mamoru Takaishi, Yuichi Suzuki, Tasuku Ishida
  • Publication number: 20110152253
    Abstract: A compound represented by the general formula (I): or a pharmaceutically acceptable salt thereof, has an A? production inhibitory effect or a BACE1 inhibitory effect and is useful as a prophylactic or therapeutic agent for a neurodegenerative disease caused by A? and typified by Alzheimer-type dementia.
    Type: Application
    Filed: July 24, 2009
    Publication date: June 23, 2011
    Applicant: Eisai R&D Management Co., Ltd
    Inventors: Takafumi Motoki, Toshihiko Kaneko, Noboru Yamamoto, Afzal Khan
  • Publication number: 20100317850
    Abstract: Disclosed is a compound represented by General formula (I), a pharmaceutically acceptable salt thereof, or a solvate of the compound or the pharmaceutically acceptable salt, which has an inhibitory activity of the production of A? or a BACE1-inhibiting activity, and is therefore useful as a prophylactic or therapeutic agent for A?-induced neurodegenerative diseases typified by Alzheimer-type dementia. Wherein the ring A represents a C6-14 aryl group or the like; L represents —NReCO— [wherein Re represents a hydrogen atom or the like] or the like; the ring B represents a C6-14 aryl group or the like; X represents a C1-3 alkylene group or the like; Y represents a single bond or the like; Z represents a C1-3 alkylene group or the like; R1 and R2 independently represent a hydrogen atom or the like; and R3, R4, R5 and R6 independently represent a hydrogen atom, a halogen atom or the like.
    Type: Application
    Filed: January 16, 2009
    Publication date: December 16, 2010
    Inventors: Yuichi Suzuki, Takafumi Motoki, Toshihiko Kaneko, Mamoru Takaishi, Tasuku Ishida, Kunitoshi Takeda, Yoichi Kita, Noboru Yamamoto, Afzal Khan, Paschalis Dimopoulos
  • Publication number: 20100093999
    Abstract: A compound represented by the general formula: wherein Ring A is a C6-14 aryl group or the like, L is —NRLCO— or the like (wherein RL is a hydrogen atom or the like), Ring B is a C6-14 aryl group or the like, X is a C1-3 alkylene group or the like, Y is a C1-3 alkylene group or the like, Z is an oxygen atom or the like, R1 and R2 are each independently a hydrogen atom or the like, and R3, R4, R5 and R6 are independently a hydrogen atom, a halogen atom or the like, or a pharmaceutically acceptable salt thereof, or a solvate thereof, has an A? production inhibitory effect or a BACE1 inhibitory effect and is useful as a therapeutic agent for a neurodegenerative disease caused by A? and typified by Alzheimer-type dementia.
    Type: Application
    Filed: September 28, 2009
    Publication date: April 15, 2010
    Applicant: EISAI R&D MANAGEMENT CO., LTD.
    Inventors: Takafumi Motoki, Kunitoshi Takeda, Yoichi Kita, Mamoru Takaishi, Yuichi Suzuki, Tasuku Ishida
  • Publication number: 20090209755
    Abstract: A compound represented by the general formula: or a pharmaceutically acceptable salt thereof or a solvate thereof, wherein Ring A is a C6-14 aryl group or the like, L is —NReCO— or the like (wherein Re is a hydrogen atom or the like), Ring B is a C6-14 aryl group or the like, X is a C1-3 alkylene group or the like, Y is a single bond or the like, Z is a C1-3 alkylene group or the like, R1 and R2 are each independently a hydrogen atom or the like, and R3, R4, R5 and R6 are independently a hydrogen atom, a halogen atom or the like, has an A? production inhibitory effect or a BACE1 inhibitory effect and is useful as a prophylactic or therapeutic agent for a neurodegenerative disease caused by A? and typified by Alzheimer-type dementia.
    Type: Application
    Filed: January 16, 2009
    Publication date: August 20, 2009
    Inventors: Yuichi SUZUKI, Takafumi MOTOKI, Toshihiko KANEKO, Mamoru TAKAISHI, Tasuku ISHIDA, Yoichi KITA, Kunitoshi TAKEDA, Noboru YAMAMOTO, Afzal KHAN, Paschalis DIMOPOULOS
  • Publication number: 20090054397
    Abstract: The present invention provides a novel compound having an excellent JNK inhibitory effect. That is, it provides a compound represented by the following formula, a salt thereof or a hydrate of them. Wherein R1 designates —(CO)h—(NRa)j—(CRb?CRc)k—Ar (wherein Ra, Rb and Rc each independently designate a hydrogen atom, a halogen atom, hydroxyl group, an optionally substituted C1-6 alkyl group or the like; Cy designates a 5- or 6-membered heteroaryl; and V each independently designate the formula -L-X—Y (wherein L designates a single bond, an optionally substituted C1-6 alkylene group or the like; X designates a single bond or the formula -A- (wherein A designates NR2, O, CO, S, SO or SO2) and so on; and Y designates a hydrogen atom, a halogen atom, nitro group or the like).
    Type: Application
    Filed: April 29, 2008
    Publication date: February 26, 2009
    Inventors: Norihito Ohi, Nobuaki Sato, Motohiro Soejima, Takashi Doko, Taro Terauchi, Yoshimitsu Naoe, Takafumi Motoki
  • Patent number: 7429609
    Abstract: The present invention provides a novel compound having an excellent JNK inhibitory effect. That is, it provides a compound represented by the following formula, a salt thereof or a hydrate of them. Wherein R1 designates —(CO)h—(NRa)j—(CRb?CRc)k—Ar (wherein Ra, Rb and Rc each independently designate a hydrogen atom, a halogen atom, hydroxyl group, an optionally substituted C1-6 alkyl group or the like; Cy designates a 5- or 6-membered heteroaryl; and V each independently designate the formula -L-X—Y (wherein L designates a single bond, an optionally substituted C1-6 alkylene group or the like; X designates a single bond or the formula -A- (wherein A designates NR2, O, CO, S, SO or SO2) and so on; and Y designates a hydrogen atom, a halogen atom, nitro group or the like).
    Type: Grant
    Filed: May 29, 2003
    Date of Patent: September 30, 2008
    Assignee: Eisai R & D Management Co., Ltd.
    Inventors: Norihito Ohi, Nobuaki Sato, Motohiro Soejima, Takashi Doko, Taro Terauchi, Yoshimitsu Naoe, Takafumi Motoki
  • Publication number: 20050261339
    Abstract: The present invention provides a novel compound having an excellent JNK inhibitory effect. That is, it provides a compound represented by the following formula, a salt thereof or a hydrate of them. Wherein R1 designates —(CO)h—(NRa)j—(CRb?CRc)k—Ar (wherein Ra, Rb and Rc each independently designate a hydrogen atom, a halogen atom, hydroxyl group, an optionally substituted C1-6 alkyl group or the like; Cy designates a 5- or 6-membered heteroaryl; and V each independently designate the formula -L-X—Y (wherein L designates a single bond, an optionally substituted C1-6 alkylene group or the like; X designates a single bond or the formula -A- (wherein A designates NR2, O, CO, S, SO or SO2) and so on; and Y designates a hydrogen atom, a halogen atom, nitro group or the like).
    Type: Application
    Filed: May 29, 2003
    Publication date: November 24, 2005
    Inventors: Norihito Ohi, Nobuaki Sato, Motohiro Soejima, Takashi Doko, Taro Terauchi, Yoshimitsu Naoe, Takafumi Motoki